Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

C Sweeney, S Bracarda, CN Sternberg, KN Chi… - The Lancet, 2021 - thelancet.com
Summary Background The PI3K/AKT and androgen-receptor pathways are dysregulated in
metastatic castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN …
被引用次数：231 相关文章

[引用][C] Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase …

C Sweeney, S Bracarda, CN Sternberg… - The …, 2021 - produccioncientifica.ucm.es
Background: The PI3K/AKT and androgen-receptor pathways are dysregulated in metastatic
castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN-loss status …

[引用][C] Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase …

C Sweeney, S Bracarda, CN Sternberg, KN Chi… - The Lancet, 2021 - cir.nii.ac.jp
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer
(IPATential150): a multicentre, randomised, double-blind, phase 3 trial | CiNii Research CiNii …

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

C Sweeney, S Bracarda, CN Sternberg, KN Chi… - The Lancet, 2021 - Elsevier
Summary Background The PI3K/AKT and androgen-receptor pathways are dysregulated in
metastatic castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN …

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

C Sweeney, S Bracarda, CN Sternberg, KN Chi… - The Lancet, 2021 - pure.au.dk
Background: The PI3K/AKT and androgen-receptor pathways are dysregulated in metastatic
castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN-loss status …

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

C Sweeney, S Bracarda… - Lancet (London …, 2021 - pubmed.ncbi.nlm.nih.gov
Background The PI3K/AKT and androgen-receptor pathways are dysregulated in metastatic
castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN-loss status …

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.

C Sweeney, S Bracarda, CN Sternberg… - Lancet (London …, 2021 - europepmc.org
Background The PI3K/AKT and androgen-receptor pathways are dysregulated in metastatic
castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN-loss status …

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

C Sweeney, S Bracarda, CN Stemberg, KN Chi… - The Lancet, 2021 - elibrary.ru
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous lethal disease
characterised by variable sensitivity to androgen-receptor signalling pathway therapy, 1, 2 …

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

C Sweeney, S Bracarda, CN Sternberg, KN Chi… - The Lancet, 2021 - Elsevier
Summary Background The PI3K/AKT and androgen-receptor pathways are dysregulated in
metastatic castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN …